UK A roundup of the biggest stories from UK pharma, including the latest agreement between the British government and industry on a renewed drug pricing clawback scheme; GSK’s search for deals in China; the London-based CRO hVIVO’s new USD 21 million contract, and the latest biotech arising from Cambridge startup incubator…
China A roundup of some of the latest pharma news from China including Pfizer’s first Asia launch of Rimegepant migraine treatment in Hong Kong; Zhifei and GSK’s shingles vaccine deal, and the collaboration between the Chinese University of Hong Kong and the Olympus Corporation. Chinese University of Hong Kong and…
UK The latest news from UK healthcare and life sciences, including the safety review of Novo Nordisk’s GLP-1 receptor agonists; VaxEquity’s grant to scale up RNA vaccine manufacturing; AstraZeneca/Quell Therapeutics cell therapy agreement and GSK’s acquisition of Bellus Health. More evidence needed on Lilly’s weight loss drug, UK watchdog says…
GSK GSK has undergone a number of changes in recent years. After driving a major transformation that began in 2017 to strengthen its R&D performance, the British multinational suffered the impact of COVID-19, spun off its consumer healthcare arm and returned to revenue growth. GSK country managers PharmaBoardroom has interviewed over…
Belgium Belgium is a hugely significant country for GSK – which employs 9,000 people in the country – as host to three of the firm’s major vaccine sites, the global headquarters for its vaccines division, and many of its oncology and haematology clinical trials. Recently installed VP and GM BeLux Emmanuelle…
Greece Before taking on his new position as VP and general manager of GSK Greece, Antonino Biroccio was already familiar with the Greek affiliate, having spent three years there in previous roles before a five year global stint that took him to Spain and Singapore. Biroccio outlines the company’s significant investments…
China A roundup of some of the biggest healthcare and pharma news from China including the exclusion of Pfizer’s Paxlovid from the country’s national insurance coverage, CanSino’s promising mRNA booster trial results, WuXi Biologics and GSK’s T-cell engager deal, Biocytogen and Hansoh’s antibody collaboration … Pfizer CEO rules out generic…
Egypt After several years abroad, Mohamed Eldababy recently returned to his home country to become GSK Egypt’s General Manager. Egypt is an important market for GSK as one of the largest multinational employers in the country with over 700 staff and two manufacturing sites. In conversation with PharmaBoardroom, Eldababy shares his…
Global The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this year’s edition that the 20 companies surveyed have firmly responded to access issues exposed by COVID-19. GSK remains at the…
Brazil After a successful international career, Andre Vivan da Silva recently returned to his native Brazil to become GSK’s country manager. He explains the importance of vaccination, in Brazil, and HIV in a country where GSK’s products treat at least half of its HIV patients. He also speaks about the company’s…
Egypt Mohamed Ali Abd El Azim gives several insights into GSK’s sizeable production footprint in Egypt, how the organisation’s aims dovetail with Egypt’s healthcare transformation, and what makes him proud to work in pharma manufacturing. Our country is improving and reshaping the healthcare industry and we as GSK have the…
LatAm GSK’s head of Emerging Markets, Luis Arosemena, comments on the strategic importance of this wide-ranging country grouping for the company, the structure of his organisation in Latin America, the importance of the country manager role, and explains how strong institutions make up for volatility in Latin America. Five of…
See our Cookie Privacy Policy Here